Article

Schizophrenia Q&A: Depot Medications in Schizophrenia Therapy

Author(s):

Peter F. Buckley, MD

In this video segment, Dr. Peter Buckley addresses 2 questions: • What factors do you consider when you offer depot medications to a patient with schizophrenia? • What can be done to encourage the use of depot medications?

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video clip, Dr Peter Buckley addresses 2 questions:

      • What factors do you consider when you offer depot medications to a patient with schizophrenia?
      • What can be done to encourage the use of depot medications?

       

      This video was originally posted on June 19, 2012 and has since been updated with permission from Dr Buckley. -Ed

      Related Videos
      New Africa /Adobestock
      Poster at APA Annual Meeting Explores the Use of GLP-1 Agonists for Antipsychotic-Associated Metabolic Issues
      “What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
      Optimizing Treatment for ADHD
      New Biomarker Study of Rapid-Acting Treatment for Acute Depression
      New Biomarker Study of Rapid-Acting Treatment for Acute Depression
      “If You Ask Me My Name”
      “If You Ask Me My Name”
      New Year, New Look
      New Year, New Look
      Work takes up one-third of a patient’s life—it is important that we pay attention to it.
      Taking and Leveraging In-Depth Work Histories: Educating the Future of Psychiatry
      An American Sunrise
      An American Sunrise
      How Full is Your New Year Glass This Year?
      How Full is Your New Year Glass This Year?
      A new treatment in development is poised to be a game-changer for patients with postpartum depression.
      Clinical Advances in Treating PPD on the Horizon
      An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
      Digital Therapeutics for the Treatment of ADHD in Children
      Related Content
      How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.
      June 5th 2024

      An Update on GLP-1 Receptor Agonists as Pharmacotherapies for AUD

      Mehdi Farokhnia, MD, MPH
      Comorbid Schizophrenia and Substance Use-Moving Toward Improved Functional Outcomes
      November 8th 2012

      Comorbid Schizophrenia and Substance Use-Moving Toward Improved Functional Outcomes

      Douglas L. Noordsy, MD
      Anita H. Clayton, MD, gives a preview of her upcoming poster presentation at the 2024 ASCP Annual Meeting.
      May 30th 2024

      Early Improvement of Symptoms in Bipolar 1 Depression

      Anita H. Clayton, MD
      Practical Approaches to Treating Early Stages of Schizophrenia
      November 8th 2012

      Practical Approaches to Treating Early Stages of Schizophrenia

      S. Charles Schulz, MD
      Anita H. Clayton, MD, welcomes us all to the 2024 ASCP Annual Meeting!
      May 29th 2024

      Exciting Possibilities at ASCP 2024

      Anita H. Clayton, MD
      An expert shares highlights from her panel presentation at the 2024 ASCP Annual Meeting.
      May 28th 2024

      Navigating New Treatments for PTSD

      Lori Davis, MD
      © 2025 MJH Life Sciences

      All rights reserved.